|
2024 Conference Publication Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLGMollee, Peter, Huart, Antoine, Mortona, Olga, Queru, Kentin, Leyronnas, Cecile, Stephanie, Harel, Sidiqi, Hasib, Desport, Estelle, Vincent, Laure, Macro, Margaret, Manier, Salomon, Jacquet, Caroline, Morel, Pierre, Horvath, Noemi, Bender, Sebastien, Olombel, Guillaume, Pascal, Virginie, Corre, Jill, Bridoux, Frank, Jaccard, Arnaud and Roussel, Murielle (2024). Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-204700 |
|
2024 Conference Publication Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) AnalysisGration, Betty, Wellard, Cameron, Moore, Elizabeth, Tan, Marianne, Murphy, Matthew, Lim, Kenneth J. C., Rowland, James, Hamad, Nada, Rajagopal, Rajeev, Mollee, Peter, Spencer, Andrew, Quach, Hang and McCaughan, Georgia (2024). Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-201790 |
|
2024 Conference Publication Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases RegistryLim, Kenneth J. C., Wellard, Cameron, Moore, Elizabeth, Gration, Betty, Augustson, Bradley, Mollee, Peter, Zhang, Jennifer, Wong Doo, Nicole, Ringkowski, Sabine, Bryant, Adam, Ninkovic, Slavisa, Hamad, Nada, McCaughan, Georgia, Kumar, Shaji, Spencer, Andrew and Quach, Hang (2024). Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-207609 |
|
2024 Conference Publication Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)Gration, Betty, Wellard, Cameron, Moore, Elizabeth, Mollee, Peter, Kerridge, Ian H., Spencer, Andrew, Shetty, Anita, Baker, Bart, Forsyth, Cecily, Heenan, Jessica, McQuilten, Zoe K, Wood, Erica M. and McCaughan, Georgia (2024). Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR). 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-199451 |
|
2024 Conference Publication Plasma Cell Enumeration By Manual and Automated Methods to Establish a Standard Pictorial ReferenceMurali, Aarya, Tobin, Joshua W.D. and Mollee, Peter (2024). Plasma Cell Enumeration By Manual and Automated Methods to Establish a Standard Pictorial Reference. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-204199 |
|
2024 Conference Publication Development of a self-reported frailty index - The SELFISia, Aaron Din How, Mollee, Peter, Berry, Robyn, Ladwa, Rahul, Ling, Victoria, Fletcher, James, Gordon, Emily, Walpole, Euan, Hanjani, Leila Shafiee, Reid, Natasha, Simonsen, Camilla and Hubbard, Ruth Eleanor (2024). Development of a self-reported frailty index - The SELFI. COSA's 51st Annual Scientific Meeting, Gold Coast, QLD, Australia, 13-15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.14117 |
|
2024 Conference Publication Comparing the outcomes of frail acute myeloid leukaemia patients undergoing systemic therapy to their fitter counterpartsSia, Aaron, Chopra, Sakshi, Ling, Victoria, Hubbard, Ruth Eleanor, Mollee, Peter, Gordon, Emily and Hanjani, Leila Shafiee (2024). Comparing the outcomes of frail acute myeloid leukaemia patients undergoing systemic therapy to their fitter counterparts. COSA's 51st Annual Scientific Meeting, Gold Coast, QLD, Australia, 13–15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.14117 |
|
2024 Conference Publication An individualised bone-targeted exercise intervention for people with multiple myeloma: study protocol of the MyeEx-impact randomised controlled trialChong, Jamie, Nicol, Jennifer, Beck, Belinda, Kay, Shelley, Hart, Nicolas, Carter, Daniel, Woodrow, Carmel, Cunningham, Brent, Farley, Morgan, Boytar, Alexander, Baguley, Brenton, Rose, Grace, Mollee, Peter and Skinner, Tina (2024). An individualised bone-targeted exercise intervention for people with multiple myeloma: study protocol of the MyeEx-impact randomised controlled trial. COSA's 51st Annual Scientific Meeting, Gold Coast, QLD, Australia, 13–15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2023 Conference Publication Serial 18F-Florbetaben Positron Emission Tomography and Cardiac Magnetic Resonance Imaging in the Evaluation of Systemic Light Chain Cardiac Amyloidosis Enhances Diagnostic and Response Assessment AccuracyRanjit Anderson, Nirija, Law, W. Phillip, Dong, Xin, Ng, Arnold C.T and Mollee, Peter (2023). Serial 18F-Florbetaben Positron Emission Tomography and Cardiac Magnetic Resonance Imaging in the Evaluation of Systemic Light Chain Cardiac Amyloidosis Enhances Diagnostic and Response Assessment Accuracy. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-186377 |
|
2023 Conference Publication Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)Quach, Hang, Lasica, Masa, Low, Michael, Mollee, Peter, Lai, Hock Choong, Wong Doo, Nicole, Hocking, Jay, Campbell, Philip, Murphy, Nicholas E., Sidiqi, M. Hasib, Routledge, David, Heenan, Jessica, Horvath, Noemi, Eek, Richard, Renwick, William E. P., Lenton, Douglas Stuart, Child, Lauren J, McCaughan, Georgia, Butcher, Belinda E, Mazumdar, Deepmala and Kalff, Anna (2023). Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand). 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-185169 |
|
2023 Conference Publication Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases RegistriesLim, Kenneth J. C., Wellard, Cameron, Moore, Elizabeth, Ninkovic, Slavisa, Chng, Wee-Joo, Spencer, Andrew, Mollee, Peter, Hocking, Jay, Ho, Phoebe Joy, Janowski, Wojt, Kim, Kihyun, Dun, Karen, McQuilten, Zoe K., Chen, Fiona and Quach, Hang (2023). Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-173896 |
|
2023 Conference Publication Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based RegimenChakravorty, Lipi, Gibbons, Anthea, Anderson, Nirija, Kwok, Fiona, Korczyk, Dariusz, Abro, Emad Uddin, Lam, Stephanie, Gibbs, Simon, Mollee, Peter and Sidiqi, M. Hasib (2023). Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-186335 |
|
2023 Conference Publication A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple MyelomaTang, Andy, Kim, Kihyun, Chen, Fiona, McQuilten, Zoe K., Mollee, Peter, Rajagopal, Rajeev, Quach, Hang, Ho, Phoebe Joy, Harrison, Simon J., Spencer, Andrew and Chng, Wee-Joo (2023). A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-178192 |
|
2023 Conference Publication High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLLSabdia, Muhammed B., Burgess, Melinda, Law, Soi Cheng, Thurgood, Lauren A., Kazakoff, Stephen, Swain, Fiona, Tobin, Joshua W.D., Mollee, Peter, Patch, Ann-Marie and Gandhi, Maher K (2023). High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLL. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-174149 |
|
2023 Conference Publication Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based ChemotherapyGibbons, Anthea, Ranjit Anderson, Nirija, Chakravorty, Lipi, Kwok, Fiona, Sidiqi, Hasib, Gibbs, Simon, Korczyk, Dariusz, Abro, Emad Uddin and Mollee, Peter (2023). Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-179219 |
|
2023 Conference Publication Identifying early suboptimal haematological response in patients with AL amyloidosis treated with bortezomib-based chemotherapyMollee, Peter, Gibbons, Anthea, Anderson, Niri Ranjit, Korczyk, Dariusz, Gibbs, Simon and Sidiqi, Hasib (2023). Identifying early suboptimal haematological response in patients with AL amyloidosis treated with bortezomib-based chemotherapy. International Myeloma Society 20th Annual Meeting and Exposition, Athens, Greece, 27-30 September 2023. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(23)02056-6 |
|
2023 Conference Publication Localised light chain (AL) amyloidosis: presentation, treatment and outcomes; an observational studyAnderson, Nirija Ranjit, Abro, Emad, Korczyk, Dariusz and Mollee, Peter (2023). Localised light chain (AL) amyloidosis: presentation, treatment and outcomes; an observational study. International Myeloma Society 20th Annual Meeting and Exposition, Athens, Greece, 27-30 September 2023. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(23)02060-8 |
|
2023 Conference Publication Imaging cardiac amyloidosis using 18F-florbetaben positron electron topography (PET) in systemic light chain (AL) amyloidosisAnderson, Nirija Ranjit, Tobin, Joshua, Law, Phillip and Mollee, Peter (2023). Imaging cardiac amyloidosis using 18F-florbetaben positron electron topography (PET) in systemic light chain (AL) amyloidosis. International Myeloma Society 20th Annual Meeting and Exposition, Athens, Greece, 27-30 September 2023. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(23)02059-1 |
|
2023 Conference Publication More Efficient Delivery Of High-cost Standard-of-care Therapies In Relapsed Multiple Myeloma Using Real-time Feedback Of Patient-reported Outcome Measures: The My-prompt-2 TrialMoore, Elizabeth, Harrison, Simon, Ho, P. Joy, Irving, Adam, King, Tracy, Mccaughan, Georgia, Mcquilten, Zoe, Mollee, Peter, Park, Susanna, Petrie, Dennis, Reynolds, John, Rutherford, Claudia, van Tonder, Tina, Wellard, Cameron, Wood, Erica and Spencer, Andrew (2023). More Efficient Delivery Of High-cost Standard-of-care Therapies In Relapsed Multiple Myeloma Using Real-time Feedback Of Patient-reported Outcome Measures: The My-prompt-2 Trial. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000977464.68933.f0 |
|
2022 Conference Publication Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA TrialPerrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji K., Bahlis, Nizar Jacques, Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Pei, Huiling, Gupta, Niodita, Kaila, Shuchita, Matt, Kathryn, Gries, Katharine S., Carson, Robin, Borgsten, Fredrik and Weisel, Katja (2022). Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-165524 |
